Efficacy of Zhenyuan capsule as adjuvant therapy for chronic heart failure: a Meta-analysis

Abstract

Abstract:

AIM: To systematically review the efficacy of Zhenyuan capsule combined with western medicine for chronic heart failure. METHODS: Databases including PubMed, The Cochrane Library, EMbase, CBM, CNKI, VIP, Wanfang were searched to collect randomized controlled trials about Zhenyuan capsule in treating chronic heart failure. Valid data were selected for a Meta-analysis by document screening and quality evaluation. RESULTS: A total 11 RCTs involving 1 006 cases were included. The results of Meta-analysis showed that the combination of Zhenyuan capsule and western medicine were superior in clinical effect［OR=4.35, 95% CI ( 2.97, 6.36), P＜0. 000 01］, left ventricular ejection fraction［MD=7.89, 95% CI (4.24, 11.54), P＜0. 000 1］, N-terminal pro brain natriuretic peptide［MD=572.24, 95% CI (427.16, 717.32), P＜0. 000 01］, cardiac output［MD=0.79, 95% CI (0.61, 0.98), P＜0. 000 01］, compared with the pure western medicine treatment. CONCLUSION: Current results indicated better clinical efficacy of the combination of Zhenyuan capsule and western medicine in the treating chronic heart failure compared with the pure western medicine treatment. Yet, due to the limited results of the included studies, it still needs to be verified by more researches.

Key words: Zhenyuan capsule, chronic heart failure, randomized controlled trial, Meta-analysis

CLC Number:

R287

WU Changjuan, TANG Tiansheng. Efficacy of Zhenyuan capsule as adjuvant therapy for chronic heart failure: a Meta-analysis[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2017, 22(3): 299-304.

References

［1］金玫, 邓扬扬. “上工治未病”对心衰防治的指导意义［J］. 北京中医药, 2008, 27(6):406-407.
［2］ Allen-La-Pointe NM, Zhou Y, Stafford JA, et al. Association between mortality and persistent use of beta blockers and angiotensinconverting enzyme inhibitors in patients with left ventricular systolic dysfunction and coronary artery disease［J］. Am J Cardiol, 2009, 103( 11): 1518-1524.
［3］Kolesnyk I, Struijk DG , Dekker FW, et al. Effects of angiotensin converting enzyme inhibitors and angiotensin II receptor blockers in patients with chronic kidney disease［J］. Neth Med, 2010, 68(1): 15-23.
［4］于永强. 芪苈强心胶囊治疗慢性心力衰竭［J］. 长春中医药大学学报, 2016, 32(1):97-98.
［5］陈茂盛. 病证结合理论及发展趋势探讨［J］. 中医杂志, 2007, 48 (10): 942-944.
［6］中华医学会心血管病学分会, 中华心血管病杂志编辑委员会. 中国心力衰竭诊断和治疗指南2014［J］. 中华心血管病杂志, 2014, 42(2): 102-121.
［7］陈晓丽, 罗智, 魏立和. 振源胶囊联合小剂量劳拉西泮治疗老年慢性心力衰竭伴焦虑症状的临床观察［J］. 中华老年多器官疾病杂志, 2015, 14(8): 602-606.
［8］陈长贵. 振源胶囊治疗慢性心力衰竭45例临床观察［J］. 中医药导报, 2014, 20(6): 106-108.
［9］段学忠, 王翔艳, 徐静, 等. 振源胶囊治疗冠心病慢性心力衰竭 42 例疗效观察［J］. 中国中医药科技, 2014,21(2): 192-193.
［10］贺鹏辉. 振源胶囊对慢性心衰患者心功能及hs-CRP、NT-proBNP的影响［J］. 检验医学与临床, 2015, 12(增刊Ⅱ): 129-132.
［11］李冬凤. 振源胶囊治疗慢性充血性心力衰竭气虚血瘀证疗效观察［J］. 河北中医, 2009, 31(11):1703-1704.
［12］李建山. 振源胶囊联合美托洛尔治疗慢性心力衰竭 66 例疗效观察［J］. 中国当代医药, 2010, 17(18): 48-49.
［13］李坤, 祁丽丽, 李永惠. 振源胶囊辅以舒适护理对慢性心力衰竭治疗的影响［J］. 中国药物经济学, 2014 (6): 205-206.
［14］廖瑜修. 振源胶囊治疗慢性心力衰竭临床观察［J］. 中成药, 2009, 31(2): 179-181.
［15］马速, 胡锦庆. 中西医结合治疗慢性心力衰竭36例观察［J］. 实用中医药杂志, 2015, 31(10): 936-937.
［16］文军, 王春梅, 丁润会, 等. 曲美他嗪联合振源胶囊治疗慢性心力衰竭的疗效观察［J］. 河北医药, 2015, 37(9): 1367-1368.
［17］杨敏, 冯萍. 振源胶囊联合帕罗西汀治疗慢性心力衰竭伴发焦虑的临床观察［J］. 中国基层医药, 2013, 20(19): 2995-2997.
［18］Kim EJ, Oh HA, Choi HJ, et al. Heat-processed ginseng saponin ameliorates the adenine-induced renal failure in rats［J］. J Ginseng Res, 2013, 37(1):87-93.
［19］Firedmann E, Thomas SA, Liu F, et al. Relationship of depress-sion, anxiety, andsocial isolation to chronic heart failure outpatient mortality［J］. Am Heart J, 2006, 152(5): 940-948.

[1]	MA Guangli, ZHANG Jing. Application of quantitative pharmacology in vaccine research and de-velopment: overview and prospect [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2023, 28(3): 315-322.
[2]	YE Hongbo, SONG Yangyang, XUE Ling, RUI Jianzhong. Meropenem population pharmacokinetic model for the Chinese elderly established by model-based META analysis [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2022, 27(9): 984-990.
[3]	XU Yonghua, SHI Xianghong. Analysis of the efficacy of torasemide combined with levocarnitine in the treatment of chronic heart failure [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2021, 26(6): 647-652.
[4]	YU Zhaolei, BAI Jianling, YU Hao, ZHAO Yang. Development of tools for clinical trial information retrieval and Meta-analysis based on R-Shiny: Taking non-small cell lung cancer as an example [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2020, 25(9): 984-991.
[5]	CHEN Wenjun, RUAN Zourong, XIANG Xiaoqiang. Development and application progress of physiologically based pharmacokinetic modeling and its combined use with other modeling methods [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2020, 25(3): 299-305.
[6]	LI Lujin, DING Junjie, LIU Dongyang, WANG Xipei, DENG Chenhui, JI Shangmin, CHEN Wenjun, MA Guangli, WANG Kun, SHENG Yucheng, XU Ling, PEI Qi, CHEN Yuancheng, CHEN Rui, SHI Jun, LI Gailing, WANG Yaning, WANG Yuzhu, XIE Haitang, ZHOU Tianyan, FANG Yi, ZHANG Jing, JIAO Zheng, HU Bei, ZHENG Qingshan. General considerations of model-based meta-analysis [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2020, 25(11): 1250-1267.
[7]	FAN Jianfeng，FANG Yi，ZHENG Chunhua. Clinical efficacy of sacubitril valsartan in the treatment of chronic heart failure [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2019, 24(7): 810-814.
[8]	LIU Yaqi, LU Mengjie, LIU Yuxiu, CHEN Yu, YUAN Yangdan, ZHOU Chongchong, LIU Man. Blinded analysis of double-blind randomized controlled trial for unequal integer ratio grouping [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2019, 24(10): 1155-1160.
[9]	SHAO Yaojun, ZHENG Tong,WANG Yanqiu,LIU Ling,YAO Yingshui. Nimodipine combined with flunarizine for preventing and treating migraine: A Meta-analysis [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2018, 23(6): 646-652.
[10]	WANG Weiyu, YU Hao. Effects of gray drugs in patients with coronary heart disease: A network Meta-analysis [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2018, 23(3): 301-307.
[11]	WU Jiaqi, YANG Qiaowen, CHEN Xiumin, HUANG Runyue, HUANG Qingchun, ZHAO Yue, WU Xiaodong. Efficacy and safety of iguratimod combined with methotrexate in rheumatoid arthritis: A systematic review and Meta-analysis [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2018, 23(10): 1132-1140.
[12]	ZHANG Xiaoyu, FANG Zhengmei, YAO Yingshui. Association of leptin and leptin receptor gene polymorphisms with hypertension: a Meta-analysis [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2017, 22(8): 910-916.
[13]	LI Yun, LI Bingsheng, ZHANG Weifang, LI Yixiu, LI Chun, PENG Juan, LAI Xin, ZHU Jing, XU Ruilai, XIONG Aizhen. Association study of miR-146a G>C polymorphisms with susceptibility of hepatocellular carcinoma in the Chinese population: a Meta-analysis [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2017, 22(7): 779-786.
[14]	RONG Guoyi, WANG Shumei, TANG Mo. Efficacy of reducing phlegm with traditional Chinese medicine on non-small cell lung cancer: a Meta-analysis [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2017, 22(7): 787-794.
[15]	LI Shaohua, YILI Hamujiang·KE Youmu, XU QI, SHAO Peipei, CHENG Lufeng. Inhibitory effects of eplerenone on the mRNA and protein expression of Kv1.3 and other channels of CD4+T lymphocyte in patients with chronic heart failure [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2017, 22(11): 1259-1264.